News & Events

In this section

Instem Co-Presenting at 52nd Annual Meeting of the Society of Toxicology

CONSHOHOCKEN, PA - February 28, 2013 - - Instem, a leading provider of IT solutions to the global early development healthcare market, announced today that Jane Reed, Director Safety Intelligence Program will be part of  a platform presentation at this year’s Society of Toxicology annual meeting in San Antonio, Texas.

The talk, entitled Cheminformatics Analysis of Compound-Cytochrome P450 Interaction Profiles is being given by Prof. Denis Fourches in the “Bioinformatics: Pathways, Profiles, and Predictions” session, on March 12th from 1:30PM to 4:15PM.

Participating institutions include the Laboratory for Molecular Modeling, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States and The Hebrew University of Jerusalem, Jerusalem, Israel.

The research uses compound-protein interaction data from Instem’s SIP ToxPath knowledgebase, combined with two public domain data sets, to assess chemical concordance across five key cytochrome P450 enzymes involved in drug metabolism. 

The cytochrome P450 family of enzymes (CYPs) are the major enzymes involved in drug metabolism, and CYP-drug interactions are a key source of adverse drug interactions, since changes in CYP enzyme activity affect the metabolism and clearance of various drugs. A good understanding of the potential CYP interactions for a new compound is an essential part of the early drug development investigation, and predictive approaches are valuable across many areas of pharmacology and toxicology, in drug development, preclinical toxicity studies, clinical trials, environmental exposures and risk assessment.

Using cheminformatics approaches, we have been able to reveal the chemical concordance across the five key enzymes (illustrating the singularity of CYP1A2 and the similarities between CYP2C9 and CYP2C19); identify new compounds both potent and selective for a particular CYP; and develop robust QSAR models to enable prediction of CYP interaction profiles for novel compounds. Such predictive models are a key resource in early drug development for assessing the metabolic profile and toxicity of a novel compound.

Instem’s exhibit at the Society of Toxicology’s ToxExpo is located at space #1137.

About Instem

Instem is a leading supplier of IT applications to the early development healthcare market, delivering compelling solutions for data collection, management and analysis across the R&D continuum. Instem applications are in use by customers worldwide, meeting the rapidly expanding needs of life science and healthcare organizations for data-driven decision making leading to safer, more effective products.

Instem’s portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonization of actionable scientific information.

Instem supports over 400 clients through full service offices in the United States, United Kingdom and China with additional locations in India and a full service distributor based in Japan.

Meeting clients at the intersection of investment & return™.

Press Contacts:

Gary Mitchell (US HQ)
Tel: 610-941-0990

Julie Jones (UK HQ)
Tel: +44 (0) 1785 825600